# US 11,027,001 B2 · Therapeutic cancer vaccines derived from a novel dendritic cell line

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,027,001 B2
- Document ID: US11027001B2
- Status: Granted
- Kind: B2
- Application number: 16/101,028
- Filed: 2018-08-10
- Published: 2019-01-03
- Granted: 2021-06-08
- Earliest claimed: 2012-12-11
- Assignees: Dcprime B.V.
- Applicants: Dcprime B.V.
- Inventors: Sandra Van Wetering; Adriana Kruisbeek
- Web page: https://patentgrep.com/patent/US11027001B2

## CPC

- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4224: {Molecules with a "CD" designation not provided for elsewhere}
- A61K 40/4243: {Wilms tumor 1 [WT1]}
- A61K 2039/80: {Vaccine for a specifically defined cancer}
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C12N 2501/02: Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/2301: Interleukin-1 (IL-1)
- C12N 2501/2304: Interleukin-4 (IL-4)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/25: Tumour necrosing factors [TNF]
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/11: from blood or immune system cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention is in the field of medical sciences. It provides means and methods for the treatment of cancer. More in particular, it provides cells and cell lines that can be developed into fully functional dendritic cells. These cells endogenously express cancer-specific antigens, which makes them particularly suited for the treatment of different kinds of cancer. More in particular, the invention relates to a precursor cell line for dendritic cells called DC-One as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012.

## Claims

### Claim 1

A method for obtaining modified cells, the method comprising:
incubating a precursor cell line as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012, under conditions that allow differentiation of the precursor cells into immature cells; and
incubating the immature cells under conditions that allow maturation of the immature cells into modified cells, wherein the modified cells are CD34-positive, CD1a-positive, CD83-positive, and CD14-negative.

### Claim 2 (depends on 1)

The method of claim 1, further comprising altering the phenotype of the modified cells by introducing genetic material into the cells and/or by knocking out endogenous genes of the cells.

### Claim 3 (depends on 2)

The method of claim 2, wherein the genetic material is a gene encoding an immunotherapeutic agent.

### Claim 4 (depends on 3)

The method of claim 3, wherein the immunotherapeutic agent is selected from the group consisting of a tumor antigen, a viral antigen, and an antigen from a parasite, bacteria, or other microorganism.

### Claim 5 (depends on 1)

The method of claim 1, wherein conditions that allow differentiation of the precursor cells comprise contacting the precursor cells with a composition comprising at least one molecule selected from the group consisting of IL-4, IL-6, PGE-2, TNF-α, TGF-β, and GM-CSF.

### Claim 6 (depends on 5)

The method of claim 5, wherein differentiation of the precursor cells comprises contacting the precursor cells with a composition comprising GM-CSF, IL-4, and TNF-α.

### Claim 7 (depends on 1)

The method of claim 1, wherein conditions that allow maturation of the immature cells comprise contacting the immature cells with a composition comprising at least one molecule selected from the group consisting of IL-6, PGE-2, TNF-α, and IL1-β.

### Claim 8 (depends on 7)

The method of claim 7, wherein maturation of the immature cells comprises contacting the immature cells with a composition comprising TNF-α, PGE2, and IL1-β.

### Claim 9 (depends on 1)

The method of claim 1, further comprising combining the modified cell with a pharmaceutically acceptable carrier to form an immunogenic composition.

### Claim 10 (depends on 1)

The method of claim 1, further comprising loading the cell with at least one further antigen.

### Claim 11 (depends on 1)

The method of claim 1, further wherein the modified cells are CD40-positive, CD80-positive, and CD86-positive.

### Claim 12 (depends on 1)

The method of claim 1, wherein the precursor cell line is of leukemic origin.

### Claim 13

A method for obtaining modified cells, the method comprising: differentiating a precursor cell line as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012, to produce modified cells, wherein the modified cells are CD34-positive, CD1a-positive, CD83-positive, and CD14-negative.

### Claim 14 (depends on 13)

The method of claim 13, further comprising combining the modified cell with a pharmaceutically acceptable carrier to form an immunogenic composition.

### Claim 15 (depends on 13)

The method of claim 13, further comprising loading the cell with at least one further antigen.

### Claim 16 (depends on 13)

The method of claim 13, further wherein the modified cells are CD40-positive, CD80-positive, and CD86-positive.

### Claim 17 (depends on 13)

The method of claim 13, wherein the precursor cell line is of leukemic origin.